Preface
- - Preface
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-3;
Foreword
- - Foreword
    Marc C. Hochberg, MD, MPH
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-3-SI-4;
Article
- - Development and clinical application of COX-2–selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
    Clifton O. Bingham III, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-5-SI-12;
  - Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility
    Bruce N. Cronstein, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-13-SI-19;
  - COX-2–selective inhibitors in the treatment of arthritis
    Thomas J. Schnitzer, MD, PhD and Marc C. Hochberg, MD, MPH
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-20-SI-30;
  - Gastrointestinal safety and tolerability of non-selective non-steroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors
    David A. Peura, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-31-SI-39;
  - Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors
    James M. Scheiman, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-40-SI-46;
  - Current perspective on the cardiovascular effects of coxibs
    Marvin A. Konstam, MD and Matthew R. Weir, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-47-SI-52;
  - Renal effects of nonselective NSAIDs and coxibs
    Matthew R. Weir, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-53-SI-58;
  - Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy
    A. Mark Fendrick, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-59-SI-64;
  - Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain
    Warren A. Katz, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-65-SI-75;
  - Emerging options with coxib therapy
    Mark J. Lema, MD, PhD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-76-SI-84;

In this issue

Sign up for alerts

Table of Contents

Coxibs: Evolution of a Revolutionary Class: Evolving Concepts and Issues Surrounding COX-2 Inhibitors

Preface

Preface

Foreword

Foreword

Article

Development and clinical application of COX-2–selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis

Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility

COX-2–selective inhibitors in the treatment of arthritis

Gastrointestinal safety and tolerability of non-selective non-steroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors

Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors

Current perspective on the cardiovascular effects of coxibs

Renal effects of nonselective NSAIDs and coxibs

Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy

Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain

Emerging options with coxib therapy

In this issue

Cleveland Clinic Journal of Medicine

Jump to